These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Schizophrenic deficit syndrome and neurologic tolerance]. Verdoux H; Bourgeois M Encephale; 1996 Jun; 22 Spec No 2():45-7. PubMed ID: 8767042 [TBL] [Abstract][Full Text] [Related]
23. Increased cortical inhibition in persons with schizophrenia treated with clozapine. Daskalakis ZJ; Christensen BK; Fitzgerald PB; Moller B; Fountain SI; Chen R J Psychopharmacol; 2008 Mar; 22(2):203-9. PubMed ID: 18308816 [TBL] [Abstract][Full Text] [Related]
24. Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex. Devoto P; Flore G; Pira L; Longu G; Gessa GL Eur J Pharmacol; 2004 Mar; 487(1-3):105-11. PubMed ID: 15033381 [TBL] [Abstract][Full Text] [Related]
25. Neurochemical interaction between dopaminergic and noradrenergic neurons in the medial prefrontal cortex. Pan WH; Yang SY; Lin SK Synapse; 2004 Jul; 53(1):44-52. PubMed ID: 15150740 [TBL] [Abstract][Full Text] [Related]
26. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Seamans JK; Yang CR Prog Neurobiol; 2004 Sep; 74(1):1-58. PubMed ID: 15381316 [TBL] [Abstract][Full Text] [Related]
27. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Pani L; Gessa GL Mol Psychiatry; 2002; 7(3):247-53. PubMed ID: 11920152 [TBL] [Abstract][Full Text] [Related]
28. Do we still believe in the dopamine hypothesis? New data bring new evidence. Abi-Dargham A Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S1-5. PubMed ID: 14972078 [TBL] [Abstract][Full Text] [Related]
29. Working memory dysfunction in schizophrenia compared to healthy controls and patients with depression: evidence from event-related fMRI. Walter H; Vasic N; Höse A; Spitzer M; Wolf RC Neuroimage; 2007 May; 35(4):1551-61. PubMed ID: 17363277 [TBL] [Abstract][Full Text] [Related]
30. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099 [TBL] [Abstract][Full Text] [Related]
31. [Incidence of the deficit form in refractory schizophrenia]. Samuelian JC Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037 [TBL] [Abstract][Full Text] [Related]
32. Dopamine enhances spatiotemporal spread of activity in rat prefrontal cortex. Bandyopadhyay S; Gonzalez-Islas C; Hablitz JJ J Neurophysiol; 2005 Feb; 93(2):864-72. PubMed ID: 15469958 [TBL] [Abstract][Full Text] [Related]
33. [Methodological constraints in evaluating anti-deficit effects]. Boyer P; Lecrubier Y; Rein W Encephale; 1996 Jun; 22 Spec No 2():25-7. PubMed ID: 8767038 [TBL] [Abstract][Full Text] [Related]
34. [Schizophrenia and neural transmission: an excess of analogical treatment?]. Tassin JP Encephale; 1996 Oct; 22 Spec No 3():91-8. PubMed ID: 9036015 [No Abstract] [Full Text] [Related]
35. Pathophysiology of schizophrenia and the role of newer antipsychotics. Risch SC Pharmacotherapy; 1996; 16(1 Pt 2):11-4. PubMed ID: 8778681 [TBL] [Abstract][Full Text] [Related]
36. A dynamical model of event-related FMRI signals in prefrontal cortex: predictions for schizophrenia. Deco G Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S65-7. PubMed ID: 16508899 [TBL] [Abstract][Full Text] [Related]
39. Dopamine neurotransmission and atypical antipsychotics in prefrontal cortex: a critical review. Masana M; Santana N; Artigas F; Bortolozzi A Curr Top Med Chem; 2012; 12(21):2357-74. PubMed ID: 23279176 [TBL] [Abstract][Full Text] [Related]